Gilead Sciences Inc. (NASDAQ: GILD) will report Q3 2025 earnings on Nov. 5. Analysts expect EPS of $2.15, down from $2.02 in the prior year. Revenue is expected to be $7.41 billion, down from $7.54 billion. The stock’s 52-week range is $78.36 to $121.82, with a dividend yield of 2.73%.

In Q2 2025, Gilead Sciences posted adjusted EPS of $2.01, beating estimates of $1.94, with revenues of $7.08 billion, surpassing expectations of $6.94 billion. CEO Daniel O’Day cited strong growth driven by key products and FDA approval for Yeztugo. The company raised revenue and earnings guidance for the year.

For full-year 2025, Gilead Sciences expects non-GAAP diluted EPS between $7.95 to $8.25. Investors can earn $100 per month from dividends by owning approximately 379 shares at $115.88 each, requiring an investment value of around $43,956. The company has consistently increased dividends for the last 10 years.

Read more at Yahoo Finance: Here’s How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock